Prosper Animal Health is focused on developing our first-in-class transformative technology with a core emphasis on vaccines and therapies for both livestock and companion animals. Our strategy is to develop, license, and commercialize a new class of oil-free vaccines and therapies based on our patented technology, IMT504. This will offer significant advantages over traditional animal vaccines: unmatched efficacy, fast and sustained immune response, broader protection, and safety.
IMT504 is a novel, first-in-class oligodeoxynucleotide (ODN), which has incredibly desirable immunostimulatory effects. IMT504 is the prototype member of the new family of non-CpG motif-containing ODNs. Functionally, IMT504 safely activates important immune cells, including plasmacytoid dendritic cells (DCs), NK and NKT cells, leads to proliferation of CD4 and CD8 T cells and B cells and release of beneficial cytokines like GM-CSF, interferon-gamma, TNF-alpha. Moreover, IMT504 has shown impressive results in animal models and humans for generating robust, diverse antibody responses and the ability to significantly reduce the amount of antigen required per dose.
IMT504 oil-free based vaccines are the next frontier of animal vaccines, providing a faster, higher level and longer lasting immune response and disease protection to ensure healthier, more productive, and better-managed animals.